BS_9NZ2D6AD
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 13.403416557161629
- age_years
- 14.025
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.657
- MYC_TARGETS_V1+0.617
- G2M_CHECKPOINT+0.575
- MYC_TARGETS_V2+0.575
- DNA_REPAIR+0.324
- SPERMATOGENESIS+0.305
- MITOTIC_SPINDLE+0.176
- PANCREAS_BETA_CELLS+0.166
- UNFOLDED_PROTEIN_RESPONSE+0.147
- OXIDATIVE_PHOSPHORYLATION+0.115
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.677
- INTERFERON_GAMMA_RESPONSE-0.630
- IL6_JAK_STAT3_SIGNALING-0.599
- TNFA_SIGNALING_VIA_NFKB-0.553
- INFLAMMATORY_RESPONSE-0.547
- ANGIOGENESIS-0.522
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.486
- ALLOGRAFT_REJECTION-0.476
- APICAL_SURFACE-0.468
- APOPTOSIS-0.468
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TZVFR600 | medulloblastoma | — | 0.979 |
| 2 | BS_EFE4YEK3 | medulloblastoma | — | 0.972 |
| 3 | BS_HE57E1RP | medulloblastoma | — | 0.971 |
| 4 | BS_W644VEVE | medulloblastoma | — | 0.968 |
| 5 | BS_ZXYDSBM9 | medulloblastoma | — | 0.967 |
| 6 | BS_09Z7TC35 | medulloblastoma | — | 0.966 |
| 7 | BS_YETBN0RQ | medulloblastoma | — | 0.964 |
| 8 | BS_QHS3V0GP | Embryonal tumors | — | 0.963 |
| 9 | BS_TYAYZ9ZW | medulloblastoma | — | 0.962 |
| 10 | BS_BSV07M7Z | medulloblastoma | — | 0.961 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.657 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.617 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.575 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.575 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.324 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.305 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.176 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.166 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.147 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.115 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.087 | Inavolisib | — uncovered |